Praxis precision medicines provides portfolio update at 2023 r&d day

Positive results from preliminary analysis of prax-222 part 1 showed 44% median reduction in seizures after three doses for scn2a-gain-of-function pediatric patients

PRAX Ratings Summary

PRAX Quant Ranking